Cas:87394-57-8 1-(3-chloropyridin-2-yl)-4-methylpiperazine manufacturer & supplier

We serve Chemical Name:1-(3-chloropyridin-2-yl)-4-methylpiperazine CAS:87394-57-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1-(3-chloropyridin-2-yl)-4-methylpiperazine

Chemical Name:1-(3-chloropyridin-2-yl)-4-methylpiperazine
CAS.NO:87394-57-8
Synonyms:1-(3-chloro-2-pyridinyl)-4-methylpiperazine;3-Chloro-2-(4-methylpiperazino)pyridine;3-CHLORO-2-(4-METHYLPIPERAZIN-1-YL)PYRIDINE
Molecular Formula:C10H14ClN3
Molecular Weight:211.69100
HS Code:2933990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:19.37000
Exact Mass:211.08800
LogP:1.48970

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 1-(3-chloro-2-pyridinyl)-4-methylpiperazine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-CHLORO-2-(4-METHYLPIPERAZIN-1-YL)PYRIDINE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-(3-chloro-2-pyridinyl)-4-methylpiperazine Use and application,3-Chloro-2-(4-methylpiperazino)pyridine technical grade,usp/ep/jp grade.


Related News: Novartis and GSK carried out a swap of its vaccine and cancer drugs back in 2015. GSK paid $5.25 billion to Novartis for its vaccine business, and Novartis sent $16 billion for GSK’s oncology programs. Tafinlar and Mekinist had already been granted FDA approval at the time of that deal, and as a part of that deal, Novartis agreed to divest its own BRAF and MEK inhibitors to avoid creating a monopoly. Pigment Red 176 manufacturers Moreover, the improved stereoselectivity further enhances product purity by ensuring that only one stereoisomer reacts where a mixture of stereoisomers is present. 2-[(4-chloro-2-nitrophenyl)diazenyl]-3-oxo-N-(2-oxo-1,3-dihydrobenzimidazol-5-yl)butanamide suppliers In the trial, 362 eligible patients were randomised (1:1) and received a fixed-dose intravenous infusion of 300mg anifrolumab or placebo every four weeks. 1-(4-Chlorophenyl)-3-Methyl-2-Pyrazolin-5-One vendor & factory.